Organon & Co Ordinary Shares OGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11
-
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
-
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
-
Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets
-
Organon Reports Results for the Second Quarter Ended June 30, 2024
-
Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024
-
11 dividend stocks with high yields expected to be well supported in 2024 per strict criteria
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 4.47
- Price/Sales
- 0.74
- Dividend Yield (Trailing)
- 6.12%
- Dividend Yield (Forward)
- 6.12%
- Total Yield
- 6.12%
Company Profile
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women’s health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Small Value
- Total Number of Employees
- 10,000
- Website
- https://www.organon.com
Comparables
Valuation
|
Metric
|
OGN
|
603896
|
002566
|
|---|---|---|---|
Price/Earnings (Normalized) | 4.47 | 20.69 | 39.98 |
Price/Book Value | 32.66 | 2.25 | 1.07 |
Price/Sales | 0.74 | 6.33 | 3.24 |
Price/Cash Flow | 4.83 | 13.42 | 17.81 |
Price/Earnings
OGN
603896
002566
Financial Strength
|
Metric
|
OGN
|
603896
|
002566
|
|---|---|---|---|
Quick Ratio | 0.84 | 3.21 | 1.81 |
Current Ratio | 1.64 | 3.70 | 5.76 |
Interest Coverage | 2.25 | 16.62 | 6.74 |
Quick Ratio
OGN
603896
002566
Profitability
|
Metric
|
OGN
|
603896
|
002566
|
|---|---|---|---|
Return on Assets (Normalized) | 9.06% | 7.55% | 1.96% |
Return on Equity (Normalized) | — | 11.00% | 2.68% |
Return on Invested Capital (Normalized) | 17.27% | 7.10% | 2.11% |
Return on Assets
OGN
603896
002566
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Tjxvjqcfmb | Vstd | $798.8 Bil | |||
| Johnson & Johnson
JNJ
| Kcmgmfpf | Ypdh | $385.9 Bil | |||
| AbbVie Inc
ABBV
| Zbfhptsf | Vbpl | $343.2 Bil | |||
| Merck & Co Inc
MRK
| Kgjhbtcj | Mlyb | $278.2 Bil | |||
| Roche Holding AG ADR
RHHBY
| Vbtjgwccb | Qbcs | $244.4 Bil | |||
| AstraZeneca PLC ADR
AZN
| Mkfdxxwbw | Qwgm | $238.9 Bil | |||
| Novartis AG ADR
NVS
| Wbhfqmvrh | Jxnj | $232.2 Bil | |||
| Amgen Inc
AMGN
| Rwljzhxllb | Ckdl | $171.8 Bil | |||
| Pfizer Inc
PFE
| Bpgybpf | Ffhz | $162.0 Bil | |||
| Sanofi SA ADR
SNY
| Bbcbbxx | Kwlzv | $140.7 Bil |
United States